Common Contracts
4 similar Global License Agreement contracts
OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation MarketGlobal License Agreement • April 26th, 2021
• Agreement expands Veloxis’ product portfolio and the continued commitment to improving the lives of transplant patients.
OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation MarketGlobal License Agreement • April 26th, 2021
• Agreement expands Veloxis’ product portfolio and the continued commitment to improving the lives of transplant patients.
OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation MarketGlobal License Agreement • April 26th, 2021
• Agreement expands Veloxis’ product portfolio and the continued commitment to improving the lives of transplant patients.
OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation MarketGlobal License Agreement • April 25th, 2021
Agreement expands Veloxis’ product portfolio and the continued commitment to improving the lives of transplant patients.
